Clinical Trial
doi: 10.1055/s-2008-1069311.[Effects of oral memantine administration on Parkinson symptoms. Results of a placebo-controlled multicenter study]
[Article in German]
- PMID:6734455
- DOI: 10.1055/s-2008-1069311
Item in Clipboard
Clinical Trial
[Effects of oral memantine administration on Parkinson symptoms. Results of a placebo-controlled multicenter study]
[Article in German]
E Schneider et al. Dtsch Med Wochenschr..
Display options
Format
Display options
Format
Abstract
The effectiveness of memantine on the symptoms of Parkinson's disease was investigated in 67 patients (39 males, 28 females) mostly between 55 and 75 years. The study was multi-center placebo-controlled with four treatment groups, i. e. patients with and without pre- and after-treatment with other anti-Parkinson medication receiving either placebo or memantine as sole or additional medication. The analysis of 61 evaluable cases showed a positive statistically significant influence on the single symptom tremor as well as on the neurological overall symptomatology (Webster-scale total score). Despite the inadequately ascertained mode of action memantine promises success particularly in milder and initial forms of the Parkinson syndrome either used as monotherapy or as an adjuvant.
Similar articles
- [Effects of intravenous administration of memantine in parkinsonian patients (author's transl)].Fischer PA, Jacobi P, Schneider E, Schönberger B.Fischer PA, et al.Arzneimittelforschung. 1977 Jul;27(7):1487-9.Arzneimittelforschung. 1977.PMID:332193Clinical Trial.German.
- Double-blind, placebo-controlled study of levodopa therapy in Parkinson's disease.Muenter MD.Muenter MD.Neurology. 1970 Dec;20(12):Suppl:6-13.Neurology. 1970.PMID:4921587Clinical Trial.No abstract available.
- Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.Storch A, Jost WH, Vieregge P, Spiegel J, Greulich W, Durner J, Müller T, Kupsch A, Henningsen H, Oertel WH, Fuchs G, Kuhn W, Niklowitz P, Koch R, Herting B, Reichmann H; German Coenzyme Q(10) Study Group.Storch A, et al.Arch Neurol. 2007 Jul;64(7):938-44. doi: 10.1001/archneur.64.7.nct60005. Epub 2007 May 14.Arch Neurol. 2007.PMID:17502459Clinical Trial.
- Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study.Merello M, Nouzeilles MI, Cammarota A, Leiguarda R.Merello M, et al.Clin Neuropharmacol. 1999 Sep-Oct;22(5):273-6.Clin Neuropharmacol. 1999.PMID:10516877Clinical Trial.
- [Treatment of Parkinson's disease with L-dopa. 77 cases].Boudin G, Castaigne P, Lhermitte F, Beck H, Guillard A, Marteau R, Pepin B, Rondot P, Raphy B.Boudin G, et al.Rev Neurol (Paris). 1970 Feb;122(2):89-102.Rev Neurol (Paris). 1970.PMID:4931719Clinical Trial.French.No abstract available.
Cited by
- A Validated Stability-indicating Reverse Phase HPLC Assay Method for the Determination of Memantine Hydrochloride Drug Substance with UV-Detection Using Precolumn Derivatization Technique.Narola B, Singh AS, Santhakumar PR, Chandrashekhar TG.Narola B, et al.Anal Chem Insights. 2010 Jul 20;5:37-45. doi: 10.4137/aci.s3936.Anal Chem Insights. 2010.PMID:20703320Free PMC article.
- Automated Stopped-Flow Fluorimetric Sensor for Biologically Active Adamantane Derivatives Based on Zone Fluidics.Tzanavaras PD, Papadimitriou S, Zacharis CK.Tzanavaras PD, et al.Molecules. 2019 Nov 3;24(21):3975. doi: 10.3390/molecules24213975.Molecules. 2019.PMID:31684129Free PMC article.
- Amantadine in Parkinson's disease.Crosby N, Deane KH, Clarke CE.Crosby N, et al.Cochrane Database Syst Rev. 2003;2003(1):CD003468. doi: 10.1002/14651858.CD003468.Cochrane Database Syst Rev. 2003.PMID:12535476Free PMC article.Review.
- Neuroprotection in glaucoma: drug-based approaches.Cheung W, Guo L, Cordeiro MF.Cheung W, et al.Optom Vis Sci. 2008 Jun;85(6):406-16. doi: 10.1097/OPX.0b013e31817841e5.Optom Vis Sci. 2008.PMID:18521010Free PMC article.Review.
- Memantine in the Prevention of Radiation-Induced Brain Damage: A Narrative Review.Scampoli C, Cammelli S, Galietta E, Siepe G, Buwenge M, Macchia G, Deodato F, Cilla S, Strigari L, Chiesa S, Morganti AG.Scampoli C, et al.Cancers (Basel). 2022 May 31;14(11):2736. doi: 10.3390/cancers14112736.Cancers (Basel). 2022.PMID:35681716Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical